FATE News and Press, Fate Therapeutics Inc. From 05/08/24

2024-05-08 17:35:57 ET More on Fate Therapeutics Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom Fate Therapeutics: Looking For A Potential Turnaround In 2024 Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript Fate Therapeutics...

Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived ce...

2024-05-05 06:27:47 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Read the full article on Seeking Alpha For further details see: Wall Street Breakfast: The Week Ahead

Off-the-shelf, CD19-targeted CAR NK Cell Product Candidate Drives Rapid and Deep Depletion of SLE Donor CD19+ B cells ADR Technology Incorporated into FT522 Induces Functional Persistence and Eliminates Alloreactive Host Immune Cells in SLE Donor PBMCs SAN DIEGO, May 03, 2024 (GLO...

Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...

2024-04-29 16:48:22 ET Summary Fate Therapeutics has a lot of potential in the cell therapy market, with multiple pipeline projects in development. Their flagship allogeneic CAR T-cell project, FT819, has shown promising results in early reports, particularly in patients with B-ce...

2024-04-29 12:09:51 ET Summary Fate Therapeutics has faced setbacks, including the termination of a partnership with Janssen Pharmaceuticals, but upcoming clinical milestones could reset the bull thesis. The company's iPSCs technology creates renewable off-the-shelf cell therapies...

Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data, from Phase 1 Study of FT819 in Relapsed / Refractory B-cell Malignancies to be Highlighted Patient Enrollment Initiated in Phase 1 Stu...

2024-04-18 16:32:07 ET More on Fate Therapeutics Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks Fate Therapeutics announces pricing of $100M underwritten offering and concurr...